Cytosorbents Corp Files 8-K on Financials
Ticker: CTSO · Form: 8-K · Filed: Mar 15, 2024 · CIK: 1175151
| Field | Detail |
|---|---|
| Company | Cytosorbents CORP (CTSO) |
| Form Type | 8-K |
| Filed Date | Mar 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: CTSO
TL;DR
CYTOSORBENTS CORP (CTSO) filed an 8-K on March 14, 2024, detailing financial results.
AI Summary
Cytosorbents Corporation filed an 8-K on March 15, 2024, reporting on its results of operations and financial condition as of March 14, 2024. The filing includes financial statements and exhibits related to the company's performance.
Why It Matters
This 8-K filing provides investors with crucial updates on Cytosorbents Corporation's financial health and operational results, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not inherently present new risks.
Key Players & Entities
- Cytosorbents Corporation (company) — Registrant
- March 14, 2024 (date) — Date of Earliest Event Reported
- March 15, 2024 (date) — Filing Date
- 305 College Road East Princeton, New Jersey 08540 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Cytosorbents Corporation's results of operations and financial condition, and to provide financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 14, 2024.
What is the filing date of this 8-K?
This 8-K filing was made on March 15, 2024.
What is the principal executive office address for Cytosorbents Corporation?
The principal executive office address for Cytosorbents Corporation is 305 College Road East, Princeton, New Jersey 08540.
What is the SIC code for Cytosorbents Corporation?
The Standard Industrial Classification (SIC) code for Cytosorbents Corporation is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-14 20:55:22
Key Financial Figures
- $0.001 — e on which registered common stock, $0.001 par value CTSO The Nasdaq Stock Marke
Filing Documents
- tm248917d1_8k.htm (8-K) — 25KB
- tm248917d1_ex99-1.htm (EX-99.1) — 113KB
- tm248917d1_ex99-1img001.jpg (GRAPHIC) — 18KB
- 0001104659-24-034674.txt ( ) — 352KB
- ctso-20240314.xsd (EX-101.SCH) — 3KB
- ctso-20240314_lab.xml (EX-101.LAB) — 33KB
- ctso-20240314_pre.xml (EX-101.PRE) — 22KB
- tm248917d1_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operation and Financial Condition On March 14, 2024, CytoSorbents Corporation (the "Company") issued a press release announcing its financial results for the quarter and twelve-months ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1.*
01
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated March 14, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 14, 2024 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer